The effects and side effects of trastuzumab injection (subcutaneous injection) (Herceptin Hylecta)

Trastuzumab injection (subcutaneous ) (Herceptin Hylecta) is a combination of the HER2/neu receptor antagonist trastuzumab and an endoglycosidase hyaluronidase, and is suitable for the treatment of HER2-overexpressing breast cancer in adults. In the HannaH study, compared with intravenous trastuzumab 8 mg/kg loading dose and 6 mg/kg maintenance dose every 3 weeks, trastuzumab exposure after subcutaneous injection (subcutaneous injection ) 600 mg every 3 weeks was non-inferior, with a geometric mean ratio of 1.3.

After subcutaneous injection of trastuzumab injection , the concentration of trastuzumab was roughly stable after the 7th cycle until the concentration increased <15% in the 13th cycle. Trastuzumab injection (subcutaneous injection) may cause serious or life-threatening reactions, which may occur during administration or within 24 hours after administration. It may also lead to severe lung damage, serious or life-threatening heart problems. Tell your doctor if you have or have had heart disease. Your doctor will order tests before and during treatment to see if your heart is working properly enough to safely receive trastuzumab injections.

It is understood that the original drug of trastuzumab injection (subcutaneous injection) has been launched in China, but the specific price and other relevant information are not yet clear. Since the drug has been on the market for a short time, it has not been included in the scope of medical insurance. At present, there are no generic drugs of Trastuzumab injection (subcutaneous injection) produced and marketed. For more information and specific prices of Trastuzumab injection (subcutaneous injection), please consult a medical consultant.